Tier 2 — strong

Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin

Antonella Riva, Ambra Corti, Gianni Belcaro, Maria R Cesarone, Mark Dugall, Giulia Vinciguerra, Beatrice Feragalli, Mariachiara Zuccarini, Roberto Eggenhoffner, Luca Giacomelli
Minerva cardioangiologica 2019 67(1):79-83

Bibliography

PubMed
PMID 30226032
DOI
10.23736/S0026-4725.18.04795-3
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignUncontrolled short-term medication non-interference study
ModelHuman intervention research
Sample30 antiplatelet users, 20 anticoagulant users and 12 metformin-treated participants
InterventionQuercetin Phytosome added to existing treatment; dose not stated in abstract
Duration10 days for platelet tests; 20 days for anticoagulant and glucose assessments
EndpointsGlucose and insulin measures; Platelet or coagulation measurements

What the study showed, in plain terms

Published in 2019, this source examined safety, interactions and special populations. Design: Uncontrolled short-term medication non-interference study. Sample/model: 30 antiplatelet users, 20 anticoagulant users and 12 metformin-treated participants. The exposure or intervention was Quercetin Phytosome added to existing treatment; dose not stated in abstract. Follow-up or treatment period: 10 days for platelet tests; 20 days for anticoagulant and glucose assessments.

The measured bleeding-time, INR and glycemic endpoints did not change significantly from baseline.

Small, uncontrolled, short-term groups. INR is not a validated quantitative measure of dabigatran exposure; this does not exclude all clinically relevant interactions.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The measured bleeding-time, INR and glycemic endpoints did not change significantly from baseline.
  • The recorded outcome domains were Glucose and insulin measures; Platelet or coagulation measurements.
  • The result applies to the tested exposure: Quercetin Phytosome added to existing treatment; dose not stated in abstract; 10 days for platelet tests; 20 days for anticoagulant and glucose assessments.

What this study can and cannot tell us

  • Small, uncontrolled, short-term groups. INR is not a validated quantitative measure of dabigatran exposure; this does not exclude all clinically relevant interactions.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects
Satish Kumar Bedada et al. · European journal of clinical pharmacology · 2018

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology